data
infant
age
month
hospit
clinic
diagnosi
dhf
obtain
four
hospit
children
hospit
ho
chi
minh
citi
vietnam
queen
sirikit
nation
institut
child
health
also
refer
bangkok
children
hospit
bangkok
thailand
children
hospit
yangon
myanmar
depart
pediatr
dr
soetomo
hospit
surabaya
indonesia
studi
data
consecut
year
either
combin
patient
routin
care
one
author
experienc
senior
academ
infecti
diseas
pediatrician
diagnos
dhfdss
infant
conform
world
health
organ
case
definit
bangkok
serum
sampl
infant
children
hospit
dhf
sent
routin
diagnost
studi
virolog
depart
arm
forc
research
institut
medic
scienc
afrim
nearli
year
afrim
provid
dengu
diagnost
servic
bangkok
children
hospit
similar
routin
diagnost
test
provid
infant
children
admit
children
hospit
yangon
virolog
depart
depart
medic
research
fiscal
constraint
limit
number
serolog
test
perform
individu
data
disassoci
identifi
present
aggreg
describ
denv
isol
attempt
acutephas
plasma
serum
sampl
thai
children
inocul
cell
intrathorac
mosquito
toxorrhynchit
splenden
denv
identifi
cell
antigenspecif
enzymelink
immunosorb
assay
elisa
panel
monoclon
antibodi
denv
plasma
serum
sampl
test
serolog
evid
acut
denv
infect
immunoglobulin
ig
igg
elisa
hemagglutin
inhibit
hai
assay
singl
specimen
u
igm
denv
consid
evid
denv
infect
denv
igmtoigg
ratio
defin
primari
infect
ratio
defin
secondari
denv
infect
serial
specimen
twofold
increas
igg
denv
absolut
valu
u
indic
secondari
infect
absenc
igm
denv
u
bangkok
hai
antibodi
denv
type
japanes
enceph
viru
measur
sera
fourfold
increas
consid
posit
acut
flaviviru
infect
infect
diagnos
primari
titer
week
onset
ill
secondari
antibodi
titer
infant
high
risk
dhfdss
figur
provid
data
publish
studi
estim
agespecif
dengu
hospit
rate
bangkok
metropolitan
area
sevenmonthold
infant
popul
age
hospit
dhfdss
modal
rate
two
time
higher
modal
hospit
rate
children
age
year
data
shown
bangkok
year
present
studi
infant
dhfdss
constitut
thai
vietnames
myanmar
indonesian
infant
children
hospit
dhf
respect
period
infant
presumpt
dhfdss
admit
hospit
bangkok
ho
chi
minh
citi
yangon
surabaya
signific
differ
age
distribut
observ
year
year
data
shown
data
year
combin
smooth
age
distribut
figur
among
infant
hospit
bangkok
children
hospit
distribut
world
health
organ
grade
respect
infant
whose
serum
sampl
test
secondarytyp
antibodi
respons
primari
infect
denv
isol
nearli
thai
infant
denv
type
recov
infant
respect
nineteen
myanmar
infant
serolog
confirm
recent
primari
infect
seven
mostli
infant
month
age
secondarytyp
dengu
haiantibodi
respons
distribut
age
dhfdss
infant
four
countri
present
similar
pattern
case
observ
infant
younger
month
largest
number
observ
infant
month
old
later
first
year
admiss
declin
nearli
baselin
thailand
indonesia
yangon
declin
admiss
revers
age
month
increas
yangon
dhf
hospit
continu
increas
second
year
life
figur
ho
chi
minh
citi
case
declin
quit
baselin
children
hospit
dhfdss
bangkok
show
classic
bimod
curv
rel
case
children
month
age
modal
age
later
life
case
year
age
figur
contrast
bimod
distribut
present
yangon
dhfdss
occur
commonli
children
modal
age
admiss
year
figur
pattern
age
distribut
infant
dhfdss
similar
four
larg
southeast
asian
countri
highli
endem
four
denv
serotyp
nearli
infant
larg
thai
smaller
myanmar
group
primari
denv
antibodi
respons
characterist
uniqu
agespecif
hospit
curv
consist
publish
observ
describ
infant
dhfdss
occurr
primari
denv
infect
primari
secondari
dhf
infect
reconcil
longstand
explanatori
hypothesi
link
sever
diseas
activ
passiv
acquir
antibodi
studi
infant
constitut
approxim
total
dhfdss
patient
lower
nearli
report
bangkok
children
hospit
differ
observ
age
distribut
curv
yangon
ho
chi
minh
citi
compar
bangkok
surabaya
yangon
curv
declin
month
rose
age
month
dip
case
occur
children
figur
ho
chi
minh
citi
infant
case
declin
end
first
year
life
baselin
contrast
thailand
indonesia
end
first
year
life
curv
approach
baselin
phenomena
may
explain
differ
averag
annual
rate
dengu
infect
yangon
modal
age
hospit
dhfdss
children
year
figur
bangkok
year
figur
bangkok
dhfdss
rare
seen
signifi
second
infect
usual
delay
child
live
two
dengu
transmiss
period
figur
among
serolog
studi
infant
dhfdss
patient
yangon
sever
age
month
older
secondari
dengu
infect
observ
consist
high
averag
annual
rate
dengu
infect
yangon
lower
infect
rate
bangkok
relationship
model
mathemat
sinc
infant
dhfdss
first
report
singl
research
studi
undertaken
group
studi
includ
bangkok
infant
primari
infect
admit
hospit
differ
age
first
year
life
hospit
mother
blood
taken
test
surrog
cord
blood
birth
analysi
dengueneutr
antibodi
show
everi
mother
studi
two
previou
denv
infect
infant
acquir
dhfdss
short
window
time
matern
neutral
antibodi
degrad
titer
approxim
matern
sera
enhanc
high
dilut
data
provid
logic
explan
observ
age
distribut
infant
dhfdss
birth
matern
antibodi
protect
infant
dengu
infect
igg
antibodi
catabol
period
risk
enhanc
infect
ensu
follow
turn
loss
enhanc
antibodi
correspond
declin
risk
dhfdss
figur
data
studi
infant
well
prospect
cohort
studi
children
demonstr
wane
absenc
heterotyp
neutral
antibodi
permit
enhanc
infect
occur
infect
enhanc
occur
lower
antibodi
concentr
neutral
immunopathogenesi
mechan
extens
studi
remark
similar
viral
infect
cat
fipv
highli
fatal
coronaviru
diseas
domest
exot
cat
cat
natur
expos
adult
fipv
develop
antibodi
titer
without
show
clinic
sign
lesion
sick
cat
believ
result
immunolog
mediat
respons
kitten
receiv
appar
compet
neutral
antibodi
fipv
transfer
colostrum
immun
queen
develop
fatal
diseas
day
infect
wildtyp
viru
passiv
transfer
antibodi
rout
produc
result
phenomenon
call
earli
death
syndrom
fipv
antibodyneg
kitten
occur
less
reliabl
delay
sever
week
anim
develop
antibodi
respons
viru
fipv
kitten
character
thrombocytopenia
elev
alt
ast
serum
bilirubin
coronavirus
pathogen
mammal
bird
larg
famili
envelop
rna
virus
nonseg
positivestrand
genom
kb
length
one
intrigu
aspect
coronaviru
replic
occurr
highfrequ
homolog
rna
recombin
togeth
porcin
transmiss
gastroenter
viru
tgev
canin
coronaviru
human
coronaviru
hcv
felin
coronavirus
form
separ
cluster
within
genu
coronaviru
includ
felin
enter
coronaviru
fipv
coronaviru
virion
possess
three
structur
protein
larg
spike
glycoprotein
small
integr
membran
glycoprotein
nucleocapsid
protein
n
protein
analog
envelop
e
nucleocapsid
c
protein
flavivirus
felin
coronavirus
divid
two
serotyp
ii
basi
crossreact
canin
coronaviru
viru
neutral
assay
type
virus
grow
poorli
tissu
cultur
show
virtual
neutral
coronaviru
sera
type
ii
virus
grow
readili
vitro
analysi
gene
structur
suggest
type
ii
virus
deriv
recombin
type
felin
coronaviru
canin
coronaviru
two
serotyp
circul
two
pathotyp
avirul
enter
virus
virul
fipv
highfrequ
mutat
may
help
coronavirus
escap
neutral
promot
infect
enhanc
fc
cell
antibodydepend
enhanc
fipv
demonstr
vitro
felin
macrophag
well
stabl
human
mous
macrophag
cell
line
cell
infect
presenc
compar
absenc
antibodi
rate
viral
entri
viral
replic
similar
condit
coronavirus
appear
enter
mononuclear
phagocyt
mean
plasma
membran
without
mark
involv
phagocyt
endosom
pathway
research
surmis
denv
antibodyviru
complex
attach
fcreceptor
virus
brought
close
cell
surfac
enter
cell
normal
mechan
enhanc
mediat
cluster
epitop
protein
result
fipv
suggest
felin
antibodi
mediat
neutral
enhanc
antibodydepend
enhanc
fipv
demonstr
bellshap
curv
increas
dilut
maxim
enhanc
occur
subneutr
titer
antibodydepend
enhanc
believ
caus
vaccin
failur
immun
live
recombin
vaccin
inocul
cat
recombin
vaccinia
viru
express
protein
fipv
sensit
cat
led
acceler
diseas
fipv
challeng
inocul
recombin
vaccinia
virus
express
n
protein
immun
vaccin
made
member
felin
coronaviru
group
tgev
canin
coronaviru
also
sensit
cat
earli
death
syndrom
flavivirida
appear
subject
high
rate
homolog
recombin
coronavirida
nonetheless
evolutionari
histori
four
dengu
serotyp
emerg
phenomenon
reminisc
felin
coronavirus
evid
denv
also
circul
two
biotyp
american
genotyp
caus
dhfdss
se
asian
genotyp
felin
coronavirus
sever
diseas
two
denv
biotyp
may
regul
crossreact
antibodi
focus
research
viralantibodi
interact
structur
level
might
clarifi
earli
pathogenesi
event
dhfdss
infant
may
provid
access
inexpens
model
studi
mechan
control
sever
dengu
infect
worker
activ
involv
develop
dengu
vaccin
may
benefit
lesson
learn
fipv
model
